Therapeutic evaluation and prognostic value of interim hybrid PET/CT with 18F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma

Hematology

Volumn 12, Issue 5, 2007, Pages 423-430

  Zhao, Jinhua ^a   Qiao, Wenli ^a   Wang, Chun ^a   Wang, Taisong ^a   Xing, Yan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Fluorine 18 fluorodeoxyglucose; Hybrid PET CT; Non Hodgkin's lymphoma; Progression free survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 34748853773     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330701393840     Document Type: Article

References (22)

1. Canellos, GP (1997) CHOP may have been part of the beginning but certainly not the end: Issues in risk-related therapy of large-cell lymphoma. J Clin Oncol, 15, pp. 1713-1716.
2. Vose, JM (1998) Current approaches to the management of non-Hodgkin's lymphoma. Semin Oncol, 25, pp. 483-491.
3. The International non-Hodgkin's lymphoma prognostic factors project (1993) A Predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
4. Mikhaeel, NG, Hutchings, M., Fields, PA, O'Doherty, MJ and Timothy, AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 16, pp. 1514-1523.
5. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J. and de Groot, T. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 13, pp. 1356-1363.
6. Jerusalem, G., Beguin, Y., Fassotte, MF, Najjar, F., Paulus, P. and Rigo, P. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85, pp. 613-618.
7. Mikhaeel, NG, Timothy, AR, O'Doherty, MJ, Hain, S. and Maisey, MN (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma, 39, pp. 543-553.
8. Torizuka, T., Nakamura, F., Kanno, T., Futatsubashi, M., Yoshikawa, E. and Okada, H. (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging, 31, pp. 22-28.
9. Kostakoglu, L., Coleman, M., Leonard, JP, Kuji, I., Zoe, H. and Goldsmith, SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med, 43, pp. 1018-1027.
10. Hoekstra, OS, Ossenkoppele, GJ, Golding, R., van Lingen, A., Visser, GW and Teule, GJ (1993) Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med, 34, pp. 1706-1710.
11. Jerusalem, G., Hustinx, R., Beguin, Y. and Fillet, G. (2005) Evaluation of therapy for lymphoma. Semin Nucl Med, 35, pp. 186-196.
12. Canellos, GP (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol, 6, pp. 931-933.
13. Segall, GM (2001) FDG PET imaging in patients with lymphoma: A clinical perspective. J Nucl Med, 42, pp. 609-610.
14. Jerusalem, G., Begiun, Y., Fassotte, MF, Belhocine, T., Hustinx, R. and Rigo, P. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol, 14, pp. 123-130.
15. Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, JA and Zhuang, H. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood, 101, pp. 3875-3876.
16. Jerusalem, G., Warland, V., Najjar, F., Paulus, P., Fassotte, MF and Fillet, G. (1999) Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun, 20, pp. 13-20.
17. Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, MF and Rigo, P. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol, 12, pp. 825-830.
18. Jerusalem, G. and Beguin, Y. (2002) Positron emission tomography in non-Hodgkin's lymphoma (NHL): Relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL. Clin Lymphoma, 3, pp. 56-61.
19. Tatsumi, M., Kitayama, H., Sugahara, H., Tokita, N., Nakamura, H. and Kanakura, Y. (2001) Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med, 42, pp. 601-608.
20. Romer, W., Hanauske, AR, Ziegler, S., Thodtmann, R., Weber, W. and Fuchs, C. (1998) Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood, 91, pp. 4464-4471.
21. Friedberg, JW, Fischman, A., Neuberg, D., Kim, H., Takvorian, T. and Ng, AK (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma, 45, pp. 85-92.
22. Hutchings, M., Mikhaeel, NG, Fields, PA, Nunan, T. and Timothy, AR (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol, 16, pp. 1160-1168.